71 related articles for article (PubMed ID: 25397535)
21. Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification.
Ananworanich J; Chomont N; Fletcher JL; Pinyakorn S; Schuetz A; Sereti I; Rerknimitr R; Dewar R; Kroon E; Vandergeeten C; Trichavaroj R; Chomchey N; Chalermchai T; Michael NL; Kim JH; Phanuphak P; Phanuphak N
J Virus Erad; 2015; 1(2):116-122. PubMed ID: 26835516
[TBL] [Abstract][Full Text] [Related]
22. Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients.
Pellegrin I; Breilh D; Coureau G; Boucher S; Neau D; Merel P; Lacoste D; Fleury H; Saux MC; Pellegrin JL; Lazaro E; Dabis F; Thiébaut R;
Antimicrob Agents Chemother; 2007 Apr; 51(4):1473-80. PubMed ID: 17296739
[TBL] [Abstract][Full Text] [Related]
23. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
[TBL] [Abstract][Full Text] [Related]
24. Switching to nevirapine-based regimens after undetectable viral load is not associated with increased risk of discontinuation due to toxicity.
Patterson P; Socías E; Pryluka D; Lapadula P; Pérez H; Cahn P
J Int AIDS Soc; 2014; 17(4 Suppl 3):19794. PubMed ID: 25397538
[TBL] [Abstract][Full Text] [Related]
25. Impact of Raltegravir or Efavirenz on Cell-Associated Human Immunodeficiency Virus-1 (HIV-1) Deoxyribonucleic Acid and Systemic Inflammation in HIV-1/Tuberculosis Coinfected Adults Initiating Antiretroviral Therapy.
Delagreverie HM; Bauduin C; De Castro N; Grinsztejn B; Chevrier M; Jouenne F; Mourah S; Kalidi I; Pilotto JH; Brites C; Tregnago Barcellos N; Amara A; Wittkop L; Molina JM; Delaugerre C
Open Forum Infect Dis; 2020 Feb; 7(2):ofz549. PubMed ID: 32083147
[TBL] [Abstract][Full Text] [Related]
26. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.
Vallejo A; Gutierrez C; Hernandez-Novoa B; Diaz L; Madrid N; Abad-Fernandez M; Dronda F; Perez-Elias MJ; Zamora J; Muñoz E; Muñoz-Fernandez MA; Moreno S
AIDS; 2012 Sep; 26(15):1885-94. PubMed ID: 22992577
[TBL] [Abstract][Full Text] [Related]
27. Accurate episomal HIV 2-LTR circles quantification using optimized DNA isolation and droplet digital PCR.
Malatinkova E; Kiselinova M; Bonczkowski P; Trypsteen W; Messiaen P; Vermeire J; Verhasselt B; Vervisch K; Vandekerckhove L; De Spiegelaere W
J Int AIDS Soc; 2014; 17(4 Suppl 3):19674. PubMed ID: 25397424
[TBL] [Abstract][Full Text] [Related]
28. The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients.
Yasuda JM; Miller C; Currier JS; Forthal DN; Kemper CA; Beall GN; Tilles JG; Capparelli EV; McCutchan JA; Haubrich RH;
Antivir Ther; 2004 Oct; 9(5):753-61. PubMed ID: 15535413
[TBL] [Abstract][Full Text] [Related]
29. HIV-1 DNA levels in peripheral blood mononuclear cells and cannabis use are associated with intermittent HIV shedding in semen of men who have sex with men on successful antiretroviral regimens.
Ghosn J; Leruez-Ville M; Blanche J; Delobelle A; Beaudoux C; Mascard L; Lecuyer H; Canestri A; Landman R; Zucman D; Ponscarme D; Rami A; Viard JP; Spire B; Rouzioux C; Costagliola D; Suzan-Monti M;
Clin Infect Dis; 2014 Jun; 58(12):1763-70. PubMed ID: 24647014
[TBL] [Abstract][Full Text] [Related]
30. Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study.
Masiá M; Martínez E; Padilla S; Gatell JM; Gutiérrez F
J Antimicrob Chemother; 2013 Feb; 68(2):409-13. PubMed ID: 23075691
[TBL] [Abstract][Full Text] [Related]
31. Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial.
Foudraine NA; Jurriaans S; Weverling GJ; Burger DM; Hoetelmans RM; Roos MT; Maas J; Miedema F; Reiss P; Portegies P; de Wolf F; Lange JM
Antivir Ther; 2001 Mar; 6(1):55-62. PubMed ID: 11417762
[TBL] [Abstract][Full Text] [Related]
32. Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART.
Nicastri E; Tommasi C; Abbate I; Bonora S; Tempestilli M; Bellagamba R; Viscione M; Rozera G; Gallo AL; Ivanovic J; Amendola A; Pucillo L; Di Perri G; Capobianchi MR; Narciso P
Antivir Ther; 2011; 16(6):797-803. PubMed ID: 21900711
[TBL] [Abstract][Full Text] [Related]
33. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
Chege D; Kovacs C; la Porte C; Ostrowski M; Raboud J; Su D; Kandel G; Brunetta J; Kim CJ; Sheth PM; Kaul R; Loutfy MR
AIDS; 2012 Jan; 26(2):167-74. PubMed ID: 22089379
[TBL] [Abstract][Full Text] [Related]
34. Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay.
Charpentier C; Choquet M; Joly V; Yeni P; Visseaux B; Caseris M; Brun-Vézinet F; Yazdanpanah Y; Peytavin G; Descamps D; Landman R
J Antimicrob Chemother; 2014 Oct; 69(10):2819-25. PubMed ID: 24948705
[TBL] [Abstract][Full Text] [Related]
35. Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.
Tinago W; O'Halloran JA; O'Halloran RM; Macken A; Lambert JS; Sheehan GJ; Mallon PW
HIV Med; 2014 Apr; 15(4):224-32. PubMed ID: 24215370
[TBL] [Abstract][Full Text] [Related]
36. Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy.
Masquelier B; Taieb A; Reigadas S; Marchou B; Cheneau C; Spire B; Charpentier C; Leport C; Raffi F; Chêne G; Descamps D;
J Antimicrob Chemother; 2011 Jul; 66(7):1582-9. PubMed ID: 21525020
[TBL] [Abstract][Full Text] [Related]
37. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Bravenboer B; Ten Kate RW; Groeneveld P; Bierman W; van der Werf Ts; Gisolf E; Richter C
HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825
[TBL] [Abstract][Full Text] [Related]
38. Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards.
Murray JM; McBride K; Boesecke C; Bailey M; Amin J; Suzuki K; Baker D; Zaunders JJ; Emery S; Cooper DA; Koelsch KK; Kelleher AD;
AIDS; 2012 Mar; 26(5):543-50. PubMed ID: 22410637
[TBL] [Abstract][Full Text] [Related]
39. Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: prevalence and associated mortality.
Durier N; Ananworanich J; Apornpong T; Ubolyam S; Kerr SJ; Mahanontharit A; Ferradini L; Ruxrungtham K; Avihingsanon A
Clin Infect Dis; 2013 Jul; 57(1):147-55. PubMed ID: 23511301
[TBL] [Abstract][Full Text] [Related]
40. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
De Castro N; Braun J; Charreau I; Pialoux G; Cotte L; Katlama C; Raffi F; Weiss L; Meynard JL; Yazdanpanah Y; Delaugerre C; Madelaine-Chambrin I; Aboulker JP; Molina JM;
Clin Infect Dis; 2009 Oct; 49(8):1259-67. PubMed ID: 19757993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
